Data & Articles

New study shows remote patient monitoring significantly improves clinical outcomes for heart failure patients

Cadence Team
Cadence Team
November 13, 2023
New study shows remote patient monitoring significantly improves clinical outcomes for heart failure patients

In a new study of 215 patients, Cadence’s remote patient monitoring solution resulted in  meaningful improvements in vitals and adherence to life-saving medications and guidelines amongst patients with heart failure with preserved ejection fraction (HFpEF) 

Today, health technology company Cadence released data highlighting the positive impact of remote patient monitoring (RPM) on health outcomes for patients with heart failure with preserved ejection fraction (HFpEF).

The results were unveiled in a poster presentation at the 2023 American Heart Association (AHA) Annual Scientific Sessions in Philadelphia and included data from 215 patients enrolled in Cadence from December 2021 to April 2023, in 11 states across the U.S. 

Whereas previous studies have demonstrated the positive impact of RPM in managing patients with heart failure with reduced ejection fraction (HFrEF), this represents one of the first longitudinal studies examining the value of RPM in treating patients with HFpEF. 

Among the most important findings highlighted in the data is a meaningful improvement in vitals and rates of adherence to guideline directed medical therapy (GDMT) in HFpEF patients who were enrolled in Cadence’s heart failure program. There was a 12x increase in the percentage of patients on all four pillars of GDMT, and a ~300% and 70% increase in the percentage of patients on sodium glucose co transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonist (MRA), respectively. Improved blood pressure control and adherence to all four pillars of GDMT  — including angiotensin receptor inhibitors (ACEi/ARB/ARNI), beta blockers, MRA and SGLT2i — significantly improves clinical outcomes and quality of life for patients with HFpEF. See Figure 1. 

“This data demonstrates how RPM can help clinicians titrate and achieve high doses of life-saving GDMT in an effective and timely manner,” said Dr. Marat Fudim, an advanced heart failure specialist and cardiologist at the Duke University Medical Center and senior author on Cadence’s AHA abstract. “Cadence’s team of multi-disciplinary heart failure clinicians are leveraging RPM and GDMT protocols to support HFpEF patients achieve better cardiovascular outcomes and quality of life.”  

Figure 1

As part of Cadence’s program, patients use a cellular-enabled blood pressure cuff, heart rate monitor and weight scale to measure their vitals daily. Cadence’s multidisciplinary clinical team monitors patient vitals and leverages technology-enabled clinical protocols to implement guideline-directed clinical interventions to patients at home. The interventions are designed to facilitate symptom, vital and medication optimization for patients with heart failure. 

Read the full abstract in the American Heart Associations’ Circulation here.

Expert Paper

A blueprint for success

Learn how health system leaders can drive innovation through effective technology partnerships.

Download the report
Employee player card
Author Bio
Cadence Team

Cadence is a health technology company helping the nation’s most patient-centric health systems deliver more consistent, proactive healthcare every day. Cadence’s remote patient intervention solution couples powerful new technology with clinical excellence, providing its patients a precise and personal level of care all outside of the four walls of the hospital.

Find out if your health system is a fit for Cadence.